PCM
RXDX

Pinz Capital Management’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

Pinz Capital Management’s Portfolio RXDX Stock Details RXDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-31,300
Closed -$572K – 595
2021
Q1 		$572K Buy
+31,300
New +$646K 0.15% 94

Other funds holding RXDX

EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
7IH
72 Investment Holdings Stamford, Connecticut $49.6M AUM 684.72% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Pinz Capital Management's RXDX Position: Q2 2021 in Review

Pinz Capital Management sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q2 2021, closing a stake of 31,300 shares — an estimated $572K sold.

Pinz Capital Management first reported a position in RXDX in Q1 2021 and held it in 1 quarter. The position peaked at $572K in Q1 2021. 49 funds tracked by Wall St. Rank hold RXDX as of Q2 2021.

  • Pinz Capital Management reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
  • Pinz Capital Management sold 31,300 Prometheus Biosciences, Inc. Common Stock shares in Q2 2021, an estimated $572K.
  • Pinz Capital Management first reported a position in Prometheus Biosciences, Inc. Common Stock in Q1 2021 and held it in 1 quarter.
  • Pinz Capital Management's Prometheus Biosciences, Inc. Common Stock position peaked at $572K in Q1 2021.
  • 49 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q2 2021.

Based on Pinz Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.